Small molecules in cardiac regeneration

The common prevalence of heart failure and limitations in its treatment are leading cause of attention and interest towards the induction of cardiac regeneration with novel approaches. Recent studies provide growing evidence regarding bona fide cardiac regeneration post genetic manipulations, administration of stimulatory factors and myocardial injuries in animal models and human studies. To this end, small molecules of different sources have been tested to treat heart failure for the development of cellular therapies. Amongst all molecules tested, p300/CBP Inhibitor VI (C15H15NO5S), c-Myc Inhibitor II (C12H11NOS2), Trp/p53 Pififthrin-α (C16H18N2OS·HBr) and Tauroursodeoxycholic Acid (C16H14O7) have the potential to induce cardiac regeneration and reduce fibroblast proliferation.